Inari Medical Reports First Quarter 2022 Financial Results
Inari Medical (NASDAQ: NARI) reported a strong first quarter for 2022, achieving revenue of $86.8 million, a 51% increase year-over-year. The company treated 8,800 patients, a sequential rise of 14%, and launched the new Intri24 device, enhancing its product line. Despite a net loss of $3.1 million, Inari revised its full-year revenue guidance upward to between $360 million and $370 million. The improved outlook reflects robust growth in U.S. operations and new product introductions.
- Revenue increased by 51% year-over-year to $86.8 million.
- 8,800 patients treated in Q1, a 14% sequential growth.
- Launched Intri24, expanding product offerings.
- Full-year revenue guidance raised to $360 million - $370 million.
- Net loss of $3.1 million in Q1 2022.
- Gross margin decreased to 88.5% from 91.9% year-over-year.
- Operating expenses rose to $79.9 million from $45.1 million year-over-year.
IRVINE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2022.
First Quarter Revenue and Business Highlights:
- Treated 8,800 patients, an increase of
14% sequentially over 7,700 patients treated in the fourth quarter of 2021. - Generated revenue of
$86.8 million in the first quarter of 2022, up4% sequentially and51% over the same quarter last year. - Launched Intri24, an introducer sheath designed to optimize the FlowTriever procedure. Intri24 is the latest device added to our FlowTriever system of purpose-built tools, all for a single price.
- Completed an offering of common stock, issuing 2.3 million shares and raising
$174.4 million to strengthen our balance sheet and further accelerate investments in all five of our growth drivers. - Ended the quarter with
$338.7 million in cash, cash equivalents and investments.
“We executed crisply across all five of our growth drivers during a highly productive first quarter,” said Bill Hoffman, CEO of Inari Medical. “We maintained our robust growth in patient treatments, presented important new data on the effectiveness of ClotTriever in patients with chronic clot, and raised additional capital to even further accelerate investment in our growth drivers. We also launched the Intri24, the second of what will be many product introductions this year. We are fully committed to better outcomes for our patients, and we remain honored and thankful to serve this mission.”
First Quarter 2022 Financial Results
Revenue was
Gross profit was
Operating expenses for the first quarter of 2022 were
Net loss was
Full-Year 2022 Revenue Guidance
Inari Medical is providing financial guidance as follows:
For the full year 2022, we are revising our revenue guidance to a range of
Webcast and Conference Call Information
Inari Medical will host a conference call to discuss the first quarter 2022 financial results after market close on Wednesday, May 4, 2022 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The conference call can be accessed live over the phone (833) 519-1265 for U.S. callers or (914) 800-3838 for international callers, using conference ID: 1854706. The live webinar can be accessed at https://ir.inarimedical.com.
About Inari Medical, Inc.
Inari Medical, Inc. is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Our current product offering consists of two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.
Forward Looking Statements
Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements include estimated full year 2022 revenue, and are based on Inari’s current expectations, forecasts, and assumptions, are subject to inherent uncertainties, risks and assumptions that are difficult to predict, and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the period ended December 31, 2021, and in its other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari.
Investor Contact:
ICR Westwicke
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com
INARI MEDICAL, INC.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share data)
(unaudited)
| Three Months Ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| Revenue | $ | 86,752 | $ | 57,397 | ||||
| Cost of goods sold | 9,967 | 4,623 | ||||||
| Gross profit | 76,785 | 52,774 | ||||||
| Operating expenses | ||||||||
| Research and development | 16,135 | 8,163 | ||||||
| Selling, general and administrative | 63,732 | 36,898 | ||||||
| Total operating expenses | 79,867 | 45,061 | ||||||
| (Loss) income from operations | (3,082 | ) | 7,713 | |||||
| Other income (expense) | ||||||||
| Interest income | 50 | 68 | ||||||
| Interest expense | (73 | ) | (73 | ) | ||||
| Other expenses | (24 | ) | (41 | ) | ||||
| Total other expenses | (47 | ) | (46 | ) | ||||
| (Loss) income before income taxes | (3,129 | ) | 7,667 | |||||
| Provision for income taxes | — | 198 | ||||||
| Net (loss) income | $ | (3,129 | ) | $ | 7,469 | |||
| Other comprehensive income (loss) | ||||||||
| Foreign currency translation adjustments | (117 | ) | (180 | ) | ||||
| Unrealized (loss) gain on available-for-sale securities | (248 | ) | 18 | |||||
| Total other comprehensive loss | (365 | ) | (162 | ) | ||||
| Comprehensive (loss) income | $ | (3,494 | ) | $ | 7,307 | |||
| Net (loss) income per share | ||||||||
| Basic | $ | (0.06 | ) | $ | 0.15 | |||
| Diluted | $ | (0.06 | ) | $ | 0.13 | |||
| Weighted average common shares used to compute net (loss) income per share | ||||||||
| Basic | 50,954,715 | 49,355,945 | ||||||
| Diluted | 50,954,715 | 55,722,293 | ||||||
INARI MEDICAL, INC.
Condensed Consolidated Balance Sheets
(in thousands, except share data)
(unaudited)
| March 31, 2022 | December 31, 2021 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 186,556 | $ | 92,752 | ||||
| Short-term investments | 152,156 | 83,348 | ||||||
| Accounts receivable, net | 44,950 | 42,351 | ||||||
| Inventories, net | 23,828 | 21,053 | ||||||
| Prepaid expenses and other current assets | 5,849 | 5,694 | ||||||
| Total current assets | 413,339 | 245,198 | ||||||
| Property and equipment, net | 18,153 | 16,471 | ||||||
| Operating lease right-of-use assets | 46,401 | 44,909 | ||||||
| Deposits and other assets | 6,216 | 981 | ||||||
| Long-term investments | — | 3,983 | ||||||
| Total assets | $ | 484,109 | $ | 311,542 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 6,066 | $ | 6,541 | ||||
| Payroll-related accruals | 19,729 | 24,433 | ||||||
| Accrued expenses and other current liabilities | 9,155 | 10,737 | ||||||
| Operating lease liabilities, current portion | 630 | 802 | ||||||
| Total current liabilities | 35,580 | 42,513 | ||||||
| Operating lease liabilities, noncurrent portion | 28,301 | 28,404 | ||||||
| Other long-term liability | 1,416 | 1,416 | ||||||
| Total liabilities | 65,297 | 72,333 | ||||||
| Commitments and contingencies (Note 7) | ||||||||
| Stockholders' equity | ||||||||
| Preferred stock, issued and outstanding as of March 31, 2022 and December 31, 2021 | — | — | ||||||
| Common stock, authorized as of March 31, 2022 and December 31, 2021; 53,022,905 and 50,313,452 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively | 53 | 50 | ||||||
| Additional paid in capital | 440,238 | 257,144 | ||||||
| Accumulated other comprehensive loss | (767 | ) | (402 | ) | ||||
| Accumulated deficit | (20,712 | ) | (17,583 | ) | ||||
| Total stockholders' equity | 418,812 | 239,209 | ||||||
| Total liabilities and stockholders' equity | $ | 484,109 | $ | 311,542 | ||||
FAQ
What were Inari Medical's Q1 2022 financial results?
How many patients did Inari Medical treat in Q1 2022?
What is Inari Medical's revenue guidance for 2022?
What new product did Inari Medical launch in Q1 2022?
What was Inari Medical's gross margin in Q1 2022?
